COMMUNIQUÉS West-GlobeNewswire

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
24/03/2026
First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
24/03/2026
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times [...]
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse
24/03/2026
Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse L’approbation chez les patients atteints d’une forme [...]
Idorsia announces the nomination of three candidates for election to the Board of Directors
24/03/2026
Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026 All Board members – current and [...]
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
24/03/2026
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, [...]
Phonak AI-Powered Hearing Aids Recognized with 2026 Artificial Intelligence Excellence Awards
24/03/2026
Phonak Virto R Infinio and Phonak Infinio Ultra Sphere honored for advancing real-world hearing performance through AI innovation STÄFA, Switzerland, March 24, 2026 (GLOBE NEWSWIRE) -- Phonak , a global leader in [...]
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
24/03/2026
NESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (the “Shares”) at a [...]
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
23/03/2026
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program [...]
Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026
23/03/2026
Conference call today, March 23, 2026, at 4:30 PM ET SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended [...]
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
23/03/2026
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
23/03/2026
Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ARD-201 obesity [...]
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
23/03/2026
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of [...]
Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis
23/03/2026
AURA Phase 2 clinical trial designed to evaluate the safety and efficacy of AP02 compared to placebo in patients with idiopathic pulmonary fibrosis (IPF) BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Avalyn, a clinical- [...]
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
23/03/2026
SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class [...]
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
23/03/2026
Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms and flexibility for [...]
AFB Research Reveals Attitudes Toward and Reach of AI with Focus on Disability
23/03/2026
WASHINGTON, March 23, 2026 (GLOBE NEWSWIRE) -- The American Foundation for the Blind today released a new study on the experiences and perceptions of people with and without disabilities using AI. The report — The AI [...]
Outlook Therapeutics Announces Proposed Public Offering
23/03/2026
ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Globus Medical Announces Board Departure
23/03/2026
AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the [...]
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
23/03/2026
Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]

Pages